Modus Therapeutics partners with Imperial College London on malaria drug
Collaboration will research the effects of Modus’ drug sevuparin in patients with severe malaria
Read More
Tag: Modus Therapeutics
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
